Fermalac SB
Natural health product licensed in Canada
- Other names
- Ibacillus, Probio SCI MC, Probiotic IBS TM
- Licence holder
- Lallemand Health Solutions (Institut Rosell)
- NPN or DIN-HM
- 80054028
- Status
- Active licence
- Licence date
- 18 September 2014
- Revision date
- 16 November 2020
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Enterococcus faecium R0026 Source : Cellule entière | 2.7 Milliards d'UFC | Not calculated |
| Enterococcus faecium R0026 Source : Enterococcus faecium R0026 | 2.7 Milliards d'UFC | Not calculated |
Non-medicinal ingredients
Lait écrémé, Sucrose, Lactose, Maltodextrine, Lactosérum, à teneur réduite en lactose, Hypromellose, Acide ascorbique, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Capsule | 1 Tous les jours |
| Adultes et adolescents | minimum: 12 years | 1 Capsule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps reduce the reappearance of reflux esophagitis (RE) symptoms following PPI treatment. Helps extend time between reappearance of reflux esophagitis (RE) symptoms following PPI treatment. Helps reduce the risk of Small Intestine Bacterial Overgrowth (SIBO) after proton pump inhibitor (PPI) treatment. Could help reduce the duration of diarrhea in those with irritable bowel syndrome.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80054028
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2020. Photograph the packaging to check whether it has changed.
Has the product changed? Photograph the packaging.